Lymphoma

Continuing medical education course from Clinical Care Options curated by Editor in Chief George Lundberg, MD, who notes: 

Recent research findings can change practices for B-cell malignancies.

Go to educational module at Clinical Care Options (requires free registration).

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

In an unusual collaboration between the U.S. Food and Drug Administration (FDA), Canada, and Australia, acalabrutinib (Calquence) has been approved as another first line therapy for chronic lymphatic leukemia/small cell lymphoma.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

Of the non-Hodgkin lymphomas, mantle cell lymphoma can be especially difficult to treat. The FDA has now announced accelerated approval for the drug zanubrutinib (Brukinsa) after it showed strong effects for patient in single-arm clinical trials.

Go to full article published by the U.S. Food and Drug Administration (FDA).

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Curated by Editor in Chief George Lundberg, MD, who notes:

Malignancies of lymphoid tissues are broadly named “lymphoma.” There are many categories and subcategories. Here is a broadly based report about non-Hodgkin lymphomas, published by Medscape in 2019.

Excerpt:

“ASCO and Friends of Cancer Research (Friends) have submitted recommended language to the U.S. Food and Drug Administration (FDA) for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO and Friends collaboration to broaden eligibility for participating in clinical trials by addressing five specific areas: minimum age requirements for trial enrollment, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies.”

Go to full article published by The ASCO Post on Aug 9, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.

In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.

Go to full article published by ASCO Daily News.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The Philadelphia Inquirer curated by Editor in Chief George Lundberg, MD, who notes: 

A new Pennsylvania law requires insurance coverage for use of FDA-approved best drugs first, rather than only after failing with a cheaper alternative.

Go to full article published by The Philadelphia Inquirer.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Research paper from Nature curated by Editor in Chief George Lundberg, MD, who notes: 

A massive study of thousands of cancers that explores the genomic basis for cancer is being reported simultaneously in dozens of journals. Nature has published this summary article.

Go to full paper published in Nature.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

During the COVID-19 pandemic, some clinical trials have gone virtual.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Excerpt from a National Geographic article:

“For now, the sole intervention for vulnerable cancer patients is social distancing and enhanced hygiene practices for their family and health care workers.”

Go to full article published by National Geographic.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from the American Society of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

For now, the only definite preventive measures vulnerable patients with cancer can use for themselves and their families are scrupulous social distancing and enhanced personal hygiene; i.e., wash your hands. For more details, ASCO is an authoritative source:

Go to full article published by the American Society of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.